HC Wainwright & Co. Reiterates Neutral on Macrogenics, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated a Neutral rating on Macrogenics (NASDAQ:MGNX) and maintained a $4 price target.
September 18, 2024 | 11:20 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. has reiterated a Neutral rating on Macrogenics and maintained a $4 price target, indicating no expected significant short-term price movement.
The reiteration of a Neutral rating and maintenance of the $4 price target suggests that the analyst does not foresee significant changes in Macrogenics' stock price in the short term. This indicates stability rather than a bullish or bearish outlook.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100